Thomas Reimann

TL;DR: The estimated size of the residual tissue burden of 108 vDNA+ cells potentially containing replication-competent proviruses, along with evidence of continuing virus production in LT despite ART, indicated two important sources for rebound following treatment interruption.

TL;DR: Recrudescent infection was detectable in multiple different LTs, and the population was genetically diverse, consistent with reactivation from a larger number of cells, underscore the challenges facing strategies to eradicate HIV infection.

TL;DR: Treating simian immunodeficiency virus-infected rhesus macaques with the antifibrotic drug pirfenidone preserved TZ architecture and was associated with significantly larger populations of CD4(+) T cells in peripheral blood and lymphoid tissues, supporting a potential role for antifIBroticDrug treatment as adjunctive therapy with ART to improve immune reconstitution.

TL;DR: Researchers studied LNs of individuals from Kampala, Uganda, before and after yellow fever vaccination and found fibrosis in LNs that was similar to that seen in HIV infection, suggesting that LN fibrosis is not limited to HIV infection and may be associated with impaired immunologic responses to vaccines.

TL;DR: Comparisons of the rate of decay in LT in people starting RAL compared to efavirenz demonstrate that RAL is not superior to EFV as judged by direct measurements of the source of virus in LT.